CompletedPhase 3

PPOS Protocol Versus GnRH Anatagonist for Expected Normal Responder Patients Undergoing ART : a Randomized Clinical Trial

Egypt328 participantsStarted 2023-01-03

Plain-language summary

The aim of this study is to compare the efficacy and safety of Progestin-Primed Ovarian Stimulation (PPOS) protocol versus the fixed GnRH antagonist protocol in expected normal responder patients undergoing intracytoplasmic sperm injection (ICSI) with frozen-thawed embryo transfer (FET). By evaluating key clinical outcomes, including ovarian response, embryological parameters, and pregnancy rates, this study seeks to determine the relative advantages and limitations of each protocol.

Who can participate

Age range18 Years – 39 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * • Women who had history of infertility for ≥1 year. * Women whose age \<40 years old by the end of the study. * Anti-Mullerian hormone \> 1.2 ng/ml. * Antral follicle count ≥ 5. Exclusion Criteria: * • Age ≥ 40 years old. * Women who are diagnosed as polycystic ovarian syndrome. * Women with endometriosis stage 3 or 4. * Documented previous IVF/ICSI cycles with no oocytes retrieved. * Women with contraindications to controlled ovarian stimulation. * Patients who refuse to share in the study.

What they're measuring

clinical pregnancy

Timeframe: 7 weeks of gestational age

Trial details

NCT IDNCT06868576

SponsorKasr El Aini Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-31

View on ClinicalTrials.gov More PPOS trials